Mupirocin
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Pharmacological action: Mupirocin - bacteriostatic broad-spectrum antibiotic for local use. Suppresses the synthesis of bacterial proteins by reversible and specific binding to isoleucyl transport RNA synthetase.
Effects on pathogens of skin infections: Staphylococcus aureus (including strains resistant to methicillin), Staphylococcus epidermidis, Staphylococcus saprophyticus and Streptococcus pyogenes (including coagulase negative strains).
It is not cross-resistant with chloramphenicol, erythromycin, fusidic acid, gentamicin, lincomycin, methicillin, neomycin, streptomycin, tetracycline.
Pharmacokinetics: Mupirocin practically does not penetrate intact skin. In case of absorption through damaged skin, it is metabolized to a microbiologically inactive metabolite, monium acid, and is rapidly excreted from the body by the kidneys.
Indications
Primary and secondary infections of the skin caused by microorganisms sensitive to mupirocin, including:
- primary skin infections - pyoderma (streptoderma, staphyloderma): impetigo, sycosis, folliculitis, furunculosis (including furuncles of the external auditory canal and auricle), ecthyma;
- secondary infections - infected eczema, infected atopic, contact and allergic dermatitis, infected injuries (abrasions, cuts, scratches, insect bites), trophic ulcers, minor (not requiring hospitalization) wounds and burns;
- prevention of bacterial lesions and their complications arising from small wounds, cuts, pressure sores.
Composition
1 g:
- Mupirocin 20 mg
excipients: macrogol 400 - 587 mg; macrogol 3350 - 393 mg
Mupirocin is marketed under different brands and generic names, and comes in different dosage forms:
Brand name | Manufacturer | Country | Dosage form |
---|---|---|---|
Bonderm | Belupo | Croatia | ointment |
Supirocin | Glenmark | India | ointment |
Supirocin B | Glenmark | India | ointment |
No customer reviews for the moment.
Dosage and Administration
Topically.
A small amount of Bonderm ointment is applied to the affected surface of the skin 2-3 times a day. The course of treatment is up to 10 days, depending on the severity of the lesion. In the absence of a clinical effect after 5 days of treatment, it is recommended to revise the diagnosis and further treatment tactics taking into account the dynamics of clinical indicators.
Bonderm® ointment can be applied using an aseptic dressing or applied under an occlusive dressing.
Children and elderly patients. Restrictions are not required.
Liver dysfunction. No correction required.
Impaired renal function. See “With Care.”
Adverse reactions
Bonderm® ointment is well tolerated. Very rarely, burning, itching and dryness at the site of application. Allergic skin reactions (swelling at the site of application, rash) on mupirocin or ointment base were rarely observed. When using the ointment in isolated cases, generalized allergic reactions were reported.
Contraindications
- hypersensitivity to any component of the drug Bonderm;
- children's age up to 3 years.
With care: a renal failure (see. "Special Instructions").
Drug interactions
Concurrent use with other topical preparations should be avoided, as this may reduce the antimicrobial activity or stability of mupirocin in the ointment.
Pregnancy and Lactation
Currently, there is insufficient data on the use of mupirocin in pregnancy, so the use of the drug is possible if the expected benefit exceeds the possible risk of complications.
Removal of the drug in breast milk is unlikely, however, the use of the drug in nursing mothers is possible if the expected benefit outweighs the risk of complications.
Special instructions
Macrogol, which is part of Bonderm ointment for external use, is absorbed from open wounds and damaged skin and excreted from the body by the kidneys, so patients with severe chronic renal failure should use the drug with caution over large areas of skin.
Avoid contact with eyes and mucous membranes. If the ointment gets into the eyes and mucous membranes, it is recommended to rinse them thoroughly with water until all the ointment remains are completely removed.
In rare cases of allergic reactions or significant irritation of the skin when using Bonderm ointment, treatment should be stopped, the affected area should be washed with water to remove residual ointment and an alternative antibiotic therapy should be prescribed.
Influence on the ability to drive a car or perform work that requires increased speed of physical and mental reactions. Adverse effects on the ability to drive vehicles and mechanisms was not observed.
Overdosage
Cases of overdose have not yet been reported.
- Brand name: Bonderm
- Active ingredient: Mupirocin
- Manufacturer: Belupo
- Country of Origin: Croatia
Studies and clinical trials of Mupirocin (Click to expand)
- Randomized clinical trial of preoperative intranasal mupirocin to reduce surgical-site infection after digestive surgery
- Phosphopantetheinylation and Specificity of Acyl Carrier Proteins in the Mupirocin Biosynthetic Cluster
- Mupirocin W (I), a Novel Pseudomonic Acid Produced by Targeted Mutation of the Mupirocin Biosynthetic Gene Cluster.
- Mupirocin H (I), a Novel Metabolite Resulting from Mutation of the HMG-CoA Synthase Analogue, mupH in Pseudomonas fluorescens.
- High-performance liquid chromatographic analysis of mupirocin in polyethylene glycols 400 and 3350 using dual ultraviolet and evaporative light scattering detection
- Shift to Pseudomonic Acid B Production in P. fluorescens NCIMB10586 by Mutation of Mupirocin Tailoring Genes mupO, mupU, mupV, and macpE
- The syntheses of carbon-14 labelled mupirocin
- Development and validation of a liquid chromatographic method for in vitro mupirocin quantification in both skin layers and percutaneous penetration studies
- Risk factors for isolation of low-level mupirocin-resistant versus -susceptible methicillin-resistant Staphylococcus aureus from patients in intensive care units
- Use of ion chromatography as an alternative method for the analysis of calcium in calcium mupirocin
- Investigation of a rifampin, fusidic-acid and mupirocin releasing silicone catheter
- The anticoagulant activity of mupirocin and its interaction with nasal secretions and serum albumin
- Sub-genotypes of mupirocin-resistant EMRSA-16 and their comparative resistance to phagocytosis
- Topical antibiotics in the treatment of superficial skin infections in general practice—A comparison of mupirocin with sodium fusidate
- Cost-effectiveness of erythromycin versus mupirocin for the treatment of impetigo in children: Rice TD, Duggan AK, DeAngelis C Pediatrics 89:210–214 Feb 1992
- Characterization of the Mupirocin Biosynthesis Gene Cluster from Pseudomonas fluorescens NCIMB 10586
- A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema
- Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema
- Mupirocin resistance in staphylococci: development and transfer of isoleucyl-tRNA synthetase-mediated resistance in vitro
- Feline acne and results of treatment with mupirocin in an open clinical trial: 25 cases (1994–96)
- Mupirocin, fusidic acid and bacitracin: activity, action and clinical uses of three topical antibiotics
- Perianal candidosis—a comparative study with mupirocin and nystatin
- A RANDOMISED CONTROLLED TRIAL OF TOPICAL EXIT SITE MUPIROCIN APPLICATION IN PATIENTS WITH CUFFED HAEMODIALYSIS CATHETERS
- Nasal mupirocin treatment of pharynx-colonized methicillin resistant Staphylococcus aureus: Preliminary study with 10 carrier infants